These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 6153747)

  • 21. Localization of co-resistance to streptomycin, kanamycin, capreomycin, and tuberactinomycin in core particles derived from ribosomes of viomycin-resistant Mycobacterium smegmatis.
    Yamada T; Mizuguchi Y; Suga K
    J Antibiot (Tokyo); 1976 Oct; 29(10):1124-6. PubMed ID: 62857
    [No Abstract]   [Full Text] [Related]  

  • 22. Molecular analysis of kanamycin and viomycin resistance in Mycobacterium smegmatis by use of the conjugation system.
    Taniguchi H; Chang B; Abe C; Nikaido Y; Mizuguchi Y; Yoshida SI
    J Bacteriol; 1997 Aug; 179(15):4795-801. PubMed ID: 9244267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Anti-bacterial activity of capreomycin, kanamycin, or viomycin against drug-resistant tubercle bacilli isolated from patients].
    Endo K
    Jpn J Antibiot; 1971 Jun; 24(3):149-51. PubMed ID: 4327336
    [No Abstract]   [Full Text] [Related]  

  • 24. Correlating rrs and eis promoter mutations in clinical isolates of Mycobacterium tuberculosis with phenotypic susceptibility levels to the second-line injectables.
    Kambli P; Ajbani K; Nikam C; Sadani M; Shetty A; Udwadia Z; Georghiou SB; Rodwell TC; Catanzaro A; Rodrigues C
    Int J Mycobacteriol; 2016 Mar; 5(1):1-6. PubMed ID: 26927983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effectiveness of the drugs of streptomycin group in experimental studies on albino mice infected with Mycobacterium tuberculosis resistant to these drugs].
    Kozulitsyna TI; Kozlova NV
    Probl Tuberk; 1976 Sep; (9):70-4. PubMed ID: 64981
    [No Abstract]   [Full Text] [Related]  

  • 26. Comparison of clinical isolates and in vitro selected mutants reveals that tlyA is not a sensitive genetic marker for capreomycin resistance in Mycobacterium tuberculosis.
    Engström A; Perskvist N; Werngren J; Hoffner SE; Juréen P
    J Antimicrob Chemother; 2011 Jun; 66(6):1247-54. PubMed ID: 21427106
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis.
    Maus CE; Plikaytis BB; Shinnick TM
    Antimicrob Agents Chemother; 2005 Feb; 49(2):571-7. PubMed ID: 15673735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Study on tuberactinomycin-N. I. In vitro Antibacterial activity of TUM-N on Tubercle bacilli isolated from patients.
    Shimizu T
    Jpn J Antibiot; 1974 Aug; 27(4):463-70. PubMed ID: 4140247
    [No Abstract]   [Full Text] [Related]  

  • 29. STUDIES ON CROSS-RESISTANCE BETWEEN CAPREOMYCIN AND CERTAIN OTHER ANTI-MYCOBACTERIAL AGENTS.
    KOSEKI Y; OKAMOTO S
    Jpn J Med Sci Biol; 1963 Feb; 16():31-8. PubMed ID: 14044251
    [No Abstract]   [Full Text] [Related]  

  • 30. Mapping of antibiotic resistance markers in Mycobacterium smegmatis.
    Suga K; Mizuguchi Y
    Jpn J Microbiol; 1974 Mar; 18(2):139-47. PubMed ID: 4139295
    [No Abstract]   [Full Text] [Related]  

  • 31. Studies on the cross-resistance of Mycobacterium tuberculosis, strain H37Rv, to aminoglycoside- and peptide-antibiotics.
    Tsukamura M; Mizuno S
    Microbiol Immunol; 1980; 24(9):777-87. PubMed ID: 6783817
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Antitubercular effect of capreomycin in vitro].
    Janowiec M
    Gruzlica; 1969 Jul; 37(7):629-35. PubMed ID: 4981783
    [No Abstract]   [Full Text] [Related]  

  • 33. [Cross resistance of Mycobacterium tuberculosis to streptomycin, kanamycin and viomycin].
    Makarevich NM; Mkrtchian SV; Afanas'eva IuP
    Antibiotiki; 1970 Apr; 15(4):345-51. PubMed ID: 4321321
    [No Abstract]   [Full Text] [Related]  

  • 34. Drug-resistance test for kanamycin and cross resistance problem in Mycobacterium tuberculosis with special reference to kanamycin, streptomycin, and viomycin.
    TSUKAMURA M
    J Antibiot (Tokyo); 1959 Jul; 12():189-91. PubMed ID: 13855139
    [No Abstract]   [Full Text] [Related]  

  • 35. Mycobacterium tuberculosis rrs A1401G mutation correlates with high-level resistance to kanamycin, amikacin, and capreomycin in clinical isolates from mainland China.
    Du Q; Dai G; Long Q; Yu X; Dong L; Huang H; Xie J
    Diagn Microbiol Infect Dis; 2013 Oct; 77(2):138-42. PubMed ID: 23948547
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The fundamental studies on antituberculous activities of lividomycin.
    Gomi J; Aoyagi T; Torikai K; Yamada Y; Fujino T
    Kekkaku; 1971 Jul; 46(7):265-9. PubMed ID: 4329783
    [No Abstract]   [Full Text] [Related]  

  • 37. In-vitro activities of aminoglycoside-aminocyclitols against mycobacteria.
    Ho YI; Chan CY; Cheng AF
    J Antimicrob Chemother; 1997 Jul; 40(1):27-32. PubMed ID: 9249201
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discordant resistance to kanamycin and amikacin in drug-resistant Mycobacterium tuberculosis.
    Krüüner A; Jureen P; Levina K; Ghebremichael S; Hoffner S
    Antimicrob Agents Chemother; 2003 Sep; 47(9):2971-3. PubMed ID: 12937004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Development of resistance of Mycobacterium tuberculosis to cycloserine, ethionamide, kanamycin, florimycin in experiments in vitro].
    Mkrtchian SV
    Antibiotiki; 1968 Oct; 13(10):907-10. PubMed ID: 4303355
    [No Abstract]   [Full Text] [Related]  

  • 40. [Drug resistance in Mycobacteria (author's transl)].
    Yamada T; Masuda K
    Kekkaku; 1976 Oct; 51(10):399-406. PubMed ID: 64637
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.